BCHE and Alzheimer disease: Since, cholinesterase inhibition improves attention and executive function in patients with AD [14], which are both associated with gait quality [15], we hypothesized that the acetylcholinesterase inhibitor (AChEI) rivastigmine would improve gait quality, as quantified by gait velocity, stride length, and cadence, in single- and dual-task gait trials.